ERBB2 and breast cancer: In human epidermal growth factor receptor 2 (EGFR2) positive breast cancer, the effectiveness of HER2/EGFR tyrosine kinase inhibitors such as lapatinib is increased following the knockdown of RICTOR or using kinase inhibitors [68].